A New Frontier in CBD Research: Targeting Acute Anxiety Symptoms
The potential anti-anxiety effects of CBD have been widely discussed within the hemp industry. Several randomized, placebo-controlled clinical trials have shown promising results in demonstrating CBD’s positive impact on patients with social anxiety disorder. Furthermore, there is evidence to suggest that CBD could potentially reduce night terrors in individuals with PTSD.
The Gap in Existing Research
While there is existing data on CBD’s effects on chronic anxiety, there is less information regarding its impact on acute anxiety symptoms, such as panic attacks. Can a high dose of CBD effectively alleviate the immediate symptoms of a panic attack? Does CBD have the potential to reduce the severity or frequency of these distressing episodes?
The Seattle-Based Study
Addressing these questions, a team of researchers based in Washington State has expressed interest in exploring the relationship between CBD and acute anxiety. Receptor Life Sciences, a Seattle-based company, recently announced significant funding for their upcoming study on CBD for anxiety.
Funding and Study Design
On April 7th, Receptor Life Sciences disclosed receiving over $9 million in funds to conduct a clinical trial focused on CBD’s effects on acute anxiety symptoms, including panic attacks and paranoia episodes. The study will also evaluate the efficacy of their proprietary dry-powder form of CBD, which is delivered via an inhaler.
The CBD Inhaler: A Game-Changer?
Receptor Life Sciences claims that their new device can deliver a specific dose of CBD directly into a patient’s lungs, resulting in immediate effects. This inhalation method is designed to facilitate rapid CBD absorption and allow individuals to experience the full benefits of CBD within minutes.
FDA Approval and Previous Research
The FDA has granted Receptor Life Sciences approval to use their CBD device for investigational purposes. The company has previously published research demonstrating the superior absorption rates of their inhaler compared to other CBD delivery methods. According to their findings, it takes just four minutes for most of the CBD from their inhaler to enter the bloodstream.
Future Implications
While detailed information about Receptor Life Sciences’ upcoming trial is not yet available, preliminary reports suggest that it will primarily focus on assessing the impact of their CBD inhaler on anxiety conditions. The research team hopes that the data generated from this trial will provide valuable insights for psychologists and doctors in the future.
Additional Developments
It is important to note that Receptor Life Sciences is also developing a CBD capsule specifically for children with autism. While the FDA has approved the company’s “absorption enhancer” for use in these autism-focused CBD pills, there is no information regarding when the testing of these supplements will take place.
Buyer Beware: Choosing the Right CBD Product
In the meantime, for individuals dealing with anxiety, it is essential to consider certain factors when selecting CBD products. Although the research conducted by companies like Receptor Life Sciences is encouraging, there are already various CBD oils, capsules, and vape cartridges available for purchase in North America. It is crucial for new customers to exercise caution and choose reputable brands when considering CBD products.
